Log in
NASDAQ:EVLO

Evelo Biosciences Stock Forecast, Price & News

$4.85
-0.12 (-2.41 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.78
Now: $4.85
$5.41
50-Day Range
$3.81
MA: $4.60
$5.73
52-Week Range
$3.01
Now: $4.85
$9.27
Volume787,887 shs
Average Volume120,356 shs
Market Capitalization$223.76 million
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Evelo Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.05 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVLO
CUSIPN/A
Phone617-577-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.88 per share

Profitability

Net Income$-85,470,000.00

Miscellaneous

Employees75
Market Cap$223.76 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$4.85
-0.12 (-2.41 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVLO News and Ratings via Email

Sign-up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions

How has Evelo Biosciences' stock price been impacted by Coronavirus (COVID-19)?

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EVLO shares have increased by 11.0% and is now trading at $4.85.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Evelo Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Evelo Biosciences
.

When is Evelo Biosciences' next earnings date?

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Evelo Biosciences
.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences Inc (NASDAQ:EVLO) announced its quarterly earnings data on Thursday, July, 30th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.08.
View Evelo Biosciences' earnings history
.

What price target have analysts set for EVLO?

5 brokers have issued 12 month target prices for Evelo Biosciences' shares. Their forecasts range from $6.00 to $17.00. On average, they expect Evelo Biosciences' share price to reach $10.33 in the next year. This suggests a possible upside of 113.1% from the stock's current price.
View analysts' price targets for Evelo Biosciences
.

Are investors shorting Evelo Biosciences?

Evelo Biosciences saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,380,000 shares, an increase of 16.0% from the August 15th total of 1,190,000 shares. Based on an average daily trading volume, of 167,900 shares, the days-to-cover ratio is presently 8.2 days. Approximately 9.3% of the company's stock are short sold.
View Evelo Biosciences' Short Interest
.

Who are some of Evelo Biosciences' key competitors?

What other stocks do shareholders of Evelo Biosciences own?

Who are Evelo Biosciences' key executives?

Evelo Biosciences' management team includes the following people:
  • Dr. Noubar B. Afeyan Ph.D., Co-founder & Chairman (Age 56)
  • Dr. Balkrishan Gill, Pres, CEO & Director (Age 54)
  • Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 61)
  • Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 52)
  • Mr. Jonathan Poole, CFO & Treasurer (Age 44)

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Who are Evelo Biosciences' major shareholders?

Evelo Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Flagship Pioneering Inc. (49.63%), FMR LLC (9.86%), BVF Inc. IL (2.82%), Artal Group S.A. (1.44%), Charles Schwab Investment Management Inc. (0.16%) and Bridgeway Capital Management Inc. (0.15%).
View institutional ownership trends for Evelo Biosciences
.

Which major investors are selling Evelo Biosciences stock?

EVLO stock was sold by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Bank of New York Mellon Corp, and Nuveen Asset Management LLC.
View insider buying and selling activity for Evelo Biosciences
.

Which major investors are buying Evelo Biosciences stock?

EVLO stock was bought by a variety of institutional investors in the last quarter, including Flagship Pioneering Inc., FMR LLC, BVF Inc. IL, Artal Group S.A., Jacobs Levy Equity Management Inc., Tudor Investment Corp Et Al, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Evelo Biosciences
.

How do I buy shares of Evelo Biosciences?

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $4.85.

How big of a company is Evelo Biosciences?

Evelo Biosciences has a market capitalization of $223.76 million. The company earns $-85,470,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis. Evelo Biosciences employs 75 workers across the globe.

What is Evelo Biosciences' official website?

The official website for Evelo Biosciences is www.evelobio.com.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.